Regional Heterogeneity of the Results of Glucagon-Like Peptide 1 Receptor Agonist Trials in Type 2 Diabetes: A Reanalysis of Individual Participant Data
Authors' conclusion
This study does not suggest any regional heterogeneity of GLP-1RA efficacy in MACE. However, a higher baseline risk and lower development status were associated with a greater benefit of these drugs.
Study context
- Population
- Patients with T2D in international RCTs of GLP-1 RA vs placebo with major cardiovascular events (MACE) as primary end point (Medline and Cochrane Library, inception to 30 June 2020)
- Participants
- 45,426 patients6 RCTs
- Comparison
- GLP-1 RA vs placebo, by region
- Outcome
- MACE
Methodological detailsrandom-effects meta-analysis, meta-regression, subgrouped by region
- Random-effects meta-analysis
- Meta-regression
- Subgrouped by region
Pooled result
As reported in the abstract
MACE, by region
- Lowest regional HR for MACE (Northern Africa)
- 0.25 (95% CI 0.05, 1.12)
- Highest regional HR for MACE (Western Europe)
- 0.98 (0.79, 1.22)
- No significant subgroup difference across regions
- P = 0.70
Further pooled results
Baseline risk of MACE by region
Per 100 patient-years
- Southern Asia (lowest)
- 2.9
- Sub-Saharan Africa (highest)
- 7.4
Meta-regression of GLP-1RA efficacy
- Baseline MACE risk and development status indexes (Human Development Index, gross domestic product) independently associated with GLP-1RA efficacy
Original publication
Regional Heterogeneity of the Results of Glucagon-Like Peptide 1 Receptor Agonist Trials in Type 2 Diabetes: A Reanalysis of Individual Participant Data. Diabetes Care. Published 27 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →